Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02598583
NCT02598583CompletedPhase 1

An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria

Alexion Pharmaceuticals, Inc.8 sites in 2 countries13 target enrollmentStarted: November 12, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
13
Locations
8
Primary Endpoint
Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

Detailed Description

The data presented is up to the Primary Completion date of the study and is for the 24-week Primary Evaluation period. The study also includes an Extension Period of up to 5 years.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male or female ≥18 years of age
  • •PNH diagnosis confirmed by documented high-sensitivity flow cytometry
  • •Documented meningococcal vaccination not more than 3 years prior to dosing
  • •Female participants of childbearing potential used highly effective contraception starting at screening and continuing until at least 24-weeks after the last dose of ALXN1210
  • •Willing and able to give written informed consent and comply with the study visit schedule

Exclusion Criteria

  • •Treatment with a complement inhibitor at any time
  • •Females who were pregnant, breastfeeding or who had a positive pregnancy test at screening or Day 1
  • •Participation in an interventional clinical study within 30 days before initiation of dosing on Day 1, or use of any experimental therapy within 30 days prior to dosing on Day 1, or within 5 half-lives of the product, whichever is greater
  • •History of allergy to excipients of ALXN1210 or known allergy to Chinese hamster ovary cell proteins
  • •Inability to comply with study requirements
  • •History of any clinically significant cardiac, hepatic, immunologic, pulmonary, or rheumatoid disease that, in the Investigator's judgment, would preclude participation
  • •Other unspecified reasons that, in the opinion of the Investigator or Sponsor, made the participant unsuitable for enrollment

Arms & Interventions

Cohort 2

Experimental

Participants were administered ALXN1210 1800 mg.

In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.

Intervention: ALXN1210 (Biological)

Cohort 1

Experimental

Participants were administered ALXN1210 900 mg.

In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.

Intervention: ALXN1210 (Biological)

Outcomes

Primary Outcomes

Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169

Time Frame: Baseline, Day 169

Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.

Secondary Outcomes

  • Cmax/D At Day 1 And Day 141(Day 1 and Day 141)
  • AUCt/ Dose-normalized (D) At Day 1(Day 1)
  • Percent Change In Haptoglobin Levels From Baseline To Day 169 And Day 1821(Baseline, Day 169, Day 1821)
  • Maximum Observed Serum Concentration (Cmax) At Day 1 And Day 141(Day 1 and Day 141)
  • Concentration At The End Of The Dosage Interval (Ctrough) At Day 1 And At Day 141(Day 1 and Day 141)
  • Percent Change In Free Hemoglobin Levels From Baseline To Day 169 And Day 1821(Baseline, Day 169, Day 1821)
  • Time To Maximum Observed Serum Concentration (Tmax) At Day 1 And Day 141(Day 1 and Day 141)
  • Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709(Baseline, Day 1709)
  • Percent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169 And Day 1933(Baseline, Day 169, Day 1933)
  • Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709(Baseline, Day 1709)
  • Percent Change In Total C5 Concentration From Baseline To Day 1709(Baseline, Day 1709)
  • Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169 And Day 1821(Baseline, Day 169, Day 1821)
  • Percent Change In D-dimer Levels From Baseline To Day 169 And Day 1821(Baseline, Day 169, Day 1821)
  • Change In Clinical Manifestations Of PNH From Baseline To Day 169 And Day 1821(Baseline, Day 169, Day 1821)
  • Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1(Day 1)
  • Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141(Day 141)
  • AUCtau/D At Day 141(Day 141)
  • Participants Experiencing Antidrug Antibodies (ADAs)(Day 1821)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (8)

Loading locations...

Similar Trials

Terminated
Phase 2
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart FailureAcute Heart Failure
NCT02151383Novartis Pharmaceuticals12
Terminated
Phase 1
M3541 in Combination With Radiotherapy in Solid TumorsSolid Tumors
NCT03225105EMD Serono Research & Development Institute, Inc.15
Completed
Phase 2
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212Cancer
NCT01072175Novartis Pharmaceuticals430
Recruiting
Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)Platinum-resistant Ovarian Cancer (PROC)Hepatocellular Carcinoma (HCC)Colorectal Cancer (CRC)HER2 Negative Breast CancerRenal Cell Carcinoma (RCC)Cutaneous Melanoma
NCT05824975GI Innovation, Inc.358
Unknown
Phase 1
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsSolid Tumors
NCT03634982Revolution Medicines, Inc.133